HC Wainwright Issues Negative Outlook for KPTI Earnings

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Research analysts at HC Wainwright cut their Q1 2025 EPS estimates for shares of Karyopharm Therapeutics in a note issued to investors on Wednesday, February 26th. HC Wainwright analyst E. White now anticipates that the company will post earnings per share of ($4.37) for the quarter, down from their prior forecast of ($4.35). HC Wainwright currently has a “Buy” rating and a $56.00 price objective on the stock. The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q2 2025 earnings at ($4.19) EPS, Q3 2025 earnings at ($3.39) EPS, Q4 2025 earnings at ($3.81) EPS, FY2025 earnings at ($15.63) EPS, FY2026 earnings at ($11.15) EPS and FY2027 earnings at ($9.05) EPS.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($3.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.90) by $0.30. The firm had revenue of $30.54 million for the quarter, compared to analyst estimates of $30.29 million.

A number of other research firms have also recently issued reports on KPTI. StockNews.com cut shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Robert W. Baird reduced their price objective on shares of Karyopharm Therapeutics from $75.00 to $54.00 and set an “outperform” rating for the company in a research note on Monday. Royal Bank of Canada reissued an “outperform” rating and set a $45.00 target price on shares of Karyopharm Therapeutics in a research report on Thursday, February 20th. Finally, Piper Sandler boosted their price target on Karyopharm Therapeutics from $60.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Karyopharm Therapeutics Price Performance

Shares of Karyopharm Therapeutics stock opened at $6.37 on Monday. The firm has a market cap of $53.64 million, a price-to-earnings ratio of -6.25 and a beta of 0.06. The stock has a 50-day simple moving average of $9.77 and a 200-day simple moving average of $11.20. Karyopharm Therapeutics has a 52-week low of $5.95 and a 52-week high of $25.50.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Velan Capital Investment Management LP bought a new stake in Karyopharm Therapeutics during the fourth quarter valued at about $27,000. Focus Partners Wealth bought a new stake in Karyopharm Therapeutics during the 4th quarter valued at approximately $31,000. TD Waterhouse Canada Inc. acquired a new stake in Karyopharm Therapeutics in the 4th quarter valued at approximately $32,000. Two Sigma Advisers LP increased its position in Karyopharm Therapeutics by 145.5% in the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock worth $52,000 after buying an additional 45,400 shares during the period. Finally, Opti Capital Management LP acquired a new position in shares of Karyopharm Therapeutics during the fourth quarter worth approximately $85,000. Institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).